Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Melinda A. Pruis"'
Autor:
Christi M. J. Steendam, G. D. Marijn Veerman, Melinda A. Pruis, Peggy Atmodimedjo, Marthe S. Paats, Cor van der Leest, Jan H. von der Thüsen, David C. Y. Yick, Esther Oomen-de Hoop, Stijn L. W. Koolen, Winand N. M. Dinjens, Ron H. N. van Schaik, Ron H. J. Mathijssen, Joachim G. J. V. Aerts, Hendrikus Jan Dubbink, Anne-Marie C. Dingemans
Publikováno v:
Cancers, Vol 12, Iss 11, p 3179 (2020)
Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the preferred treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC), not all patients benefit. We therefore explored the impact of the presen
Externí odkaz:
https://doaj.org/article/cb0bfe18d1d44afa8a6ff9aaaac67bbb
Autor:
Melinda A. Pruis, G.D. Marijn Veerman, H. Carlijne Hassing, Daan A.C. Lanser, Marthe S. Paats, Ron H.N. van Schaik, Ron H.J. Mathijssen, Olivier Manintveld, Anne-Marie C. Dingemans
Publikováno v:
JACC: CardioOncology. 5:102-113
Autor:
Nikki de Rouw, René J. Boosman, Jacobus A. Burgers, Alwin D. R. Huitema, Anne-Marie C. Dingemans, Hieronymus. J. Derijks, David M. Burger, Berber Piet, Lizza E. L. Hendriks, Bonne Biesma, Melinda A. Pruis, Daphne W. Dumoulin, Sander Croes, Ron H. J. Mathijssen, Michel M. van den Heuvel, Rob ter Heine
Publikováno v:
Cancer Chemotherapy and Pharmacology, 91, 33-42
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer Verlag
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer-Verlag
Cancer Chemotherapy and Pharmacology, 91, 1, pp. 33-42
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer Verlag
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer-Verlag
Cancer Chemotherapy and Pharmacology, 91, 1, pp. 33-42
Item does not contain fulltext PURPOSE: Pemetrexed is a chemotherapeutic drug in the treatment of non-small cell lung cancer and mesothelioma. Optimized dosing of pemetrexed based on renal function instead of body surface area (BSA) is hypothesized t
Autor:
Simon P. de Leeuw, Melinda A. Pruis, Barend J. Sikkema, Mostafa Mohseni, G. D. Marijn Veerman, Marthe S. Paats, Daphne W. Dumoulin, Egbert F. Smit, Annemie M.W. J. Schols, Ron H.J. Mathijssen, Elisabeth F.C. van Rossum, Anne-Marie C. Dingemans
Publikováno v:
Journal of Thoracic Oncology. International Association for the Study of Lung Cancer
Introduction: Alectinib is a standard-of-care treatment for metastatic ALK+ NSCLC. Weight gain is an unexplored side effect reported in approximately 10%. To prevent or intervene alectinib-induced weight gain, more insight in its extent and etiology
Autor:
Melinda A. Pruis, Floris H. Groenendijk, K. Sangeeta Badloe, Andrea van Puffelen, Debbie Robbrecht, Winand N. M. Dinjens, Stefan Sleijfer, Anne-Marie C. Dingemans, Jan H. von der Thüsen, Paul Roepman, Martijn P. Lolkema
Publikováno v:
British Journal of Cancer, 127(4), 776-783. Nature Publishing Group
Background Biomarker-guided therapy in an experimental setting has been suggested to improve patient outcomes. However, trial-specific pre-screening tests are time and tissue consuming and complicate the personalised treatment of patients eligible fo
Publikováno v:
JCO Precision Oncology. :849-853
Autor:
Nikki, de Rouw, René J, Boosman, Jacobus A, Burgers, Alwin D R, Huitema, Anne-Marie C, Dingemans, Hieronymus J, Derijks, David M, Burger, Berber, Piet, Lizza E L, Hendriks, Bonne, Biesma, Melinda A, Pruis, Daphne W, Dumoulin, Sander, Croes, Ron H J, Mathijssen, Michel M, van den Heuvel, Rob, Ter Heine
Publikováno v:
Cancer chemotherapy and pharmacology. 91(1)
Pemetrexed is a chemotherapeutic drug in the treatment of non-small cell lung cancer and mesothelioma. Optimized dosing of pemetrexed based on renal function instead of body surface area (BSA) is hypothesized to reduce pharmacokinetic variability in
Autor:
Thüsen J.H. von der, Melinda A. Pruis, A-M.C. Dingemans, Willemina R. R. Geurts-Giele, Isabelle C. Meijssen, W. Dinjens, Marthe S. Paats, Hendrikus J. Dubbink, Martijn P. Lolkema, Joachim G.J.V. Aerts
Publikováno v:
Lung Cancer, 140, 46-54. Elsevier Ireland Ltd
Objectives The oncogenic MET exon 14 skipping mutation (METex14del) is described to drive 1.3 %–5.7 % of non-small-cell lung cancer (NSCLC) and multiple studies with cMET inhibitors show promising clinical responses. RNA-based analysis seems most o
Autor:
Melinda A, Pruis, Floris H, Groenendijk, K Sangeeta, Badloe, Andrea, van Puffelen, Debbie, Robbrecht, Winand N M, Dinjens, Stefan, Sleijfer, Anne-Marie C, Dingemans, Jan H, von der Thüsen, Paul, Roepman, Martijn P, Lolkema
Publikováno v:
British journal of cancer. 127(4)
Biomarker-guided therapy in an experimental setting has been suggested to improve patient outcomes. However, trial-specific pre-screening tests are time and tissue consuming and complicate the personalised treatment of patients eligible for early-pha
Autor:
Rogier A.S. Hoek, Burhan Hussain, Jelle R. Miedema, Marleen Bakker, Marthe S. Paats, Melinda A. Pruis, Anne-Marie C. Dingemans
Publikováno v:
Cancer Cell
Cancer Cell, 38(5), 611-612. Cell Press
Cancer Cell, 38(5), 611-612. Cell Press